Hot Performing Stocks To Invest In Right Now

Shutterstock

When blue chips get too popular – like the five I’m going to show you today – these “safe stocks” can actually be dangerous to continue holding in your portfolio.

The problem with blue-chip stocks? Call it the “Curse of the Dow.” The Curse says a stock that joins the Dow Jones Industrial Average will essentially hit a wall, underperforming in the ensuing months compared to how it performed before ascension. It’s not perfect, but it’s close – since 1999, 15 of 16 stocks that have joined the Dow have averaged 1% gains over the next six months, but averaged 11% gains in the six months before inclusion.

Why? There are a few factors, but one of the most prevailing is that by the point a stock has joined the Dow, it’s typically nearing the end of its growth ramp and reaching the slower-growth “mature” part of the business cycle.

Hot Performing Stocks To Invest In Right Now: Meredith Corporation(MDP)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Meredith Corp. (NYSE: MDP) was maintained as Hold but the price target was raised to $65 (versus a $62.75 close) at Benchmark.

    Norfolk Southern Co. (NYSE: NSC) was downgraded to Underperform from Sector Perform at RBC Capital Markets.

  • [By Douglas A. McIntyre]

    Meredith Corp. (NYSE: MDP), the publishing, database and television station owner, has been described in several media reports as the most likely buyer of Time Inc. (NYSE: TIME). However, there are reports that the talks have stalled over valuation, which many experts believe will need to be above $20 a share to get the approval of Time’s board.

Hot Performing Stocks To Invest In Right Now: Arena Pharmaceuticals, Inc.(ARNA)

Advisors’ Opinion:

  • [By Paul Ausick]

    Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.

  • [By Keith Speights]

    Eisai partnered with Arena Pharmaceuticals (NASDAQ:ARNA) several years ago on obesity drug Belviq. The drug won U.S. regulatory approval in 2012, but sales have been underwhelming. As a result, Arena sold Belviq to Eisai earlier this year.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap obesity drug stock Arena Pharmaceuticals, Inc (NASDAQ: ARNA) is scheduled for after the market closes onTuesday (March 14th). Last June,Arena Pharmaceuticals announced a strategic shifting of priorities to emphasize its proprietary clinical stage pipeline and the implementation of additional cost reductions to streamline the organization to support its development programs. Among the actions to be taken is the layoff of 73% of the companys workforce which will cost approximately $6.1 million.

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.

  • [By Lisa Levin]

    Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.

Hot Performing Stocks To Invest In Right Now: Inovio Pharmaceuticals, Inc.(INO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:

    CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild

    Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.

    In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.

    Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s DNA-based vaccine approach is safe and can rapidly transition to human studies.

    Shares of Inovio Pharmaceuticalshave gained 4.3% to $9.24 at 2:50 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has dipped 0.3% to $284.29.

  • [By Lisa Levin]

    Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were also up, gaining 24 percent to $8.84 following announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response.

  • [By William Patalon III]

    In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

  • [By Keith Speights]

    A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.

Hot Performing Stocks To Invest In Right Now: lululemon athletica inc.(LULU)

Advisors’ Opinion:

  • [By Paul Ausick]

    Lululemon Athletica Inc. (NASDAQ: LULU) reported fiscal second-quarter 2017 results after markets closed Thursday afternoon. The yoga gear maker reported adjusted diluted earnings per share (EPS) of $0.39 on revenues of $581.1 million, compared with EPS of $0.38 on revenues of $514.5 million in the same period a year ago. The consensus estimates called for EPS of $0.35 on revenues of $567.6 million.

  • [By Chris Lange]

    Lululemon Athletica Inc. (NASDAQ: LULU) reported its most recently quarterly earnings after markets closed on Wednesday. The company posted $0.99 in earnings per share (EPS) and $789.9 million in revenue, versus consensus estimates from Thomson Reuters that called for $1.01 in EPS and $783.56 million in revenue. The fiscal fourth quarter from last year had $0.85 in EPS and $704.28 million in revenue.

  • [By Craig Jones]

    Najarian also noticed bullish activity in Lululemon Athletica inc. (NASDAQ: LULU). He said that short-term options traded significantly higher on private equity rumors. He has a long position in the name.

  • [By Trey Thoelcke]

    And Lululemon Athletica Inc. (NASDAQ: LULU) is expected to release its most recent quarterly results on Thursday afternoon. The consensus forecast calls for $0.35 in EPS and revenue of $567.55 million. The stock ended the week at $60.21 a share. The consensus price target is $61.97, and the 52-week range is $47.26 to $79.41.

  • [By Peter Graham]

    Athletic apparel stock Lululemon Athletica inc (NASDAQ: LULU) reported Q2 2017 earnings after the Thursday market close with results toppingexpectations as online sales surged 30% after an effort to beef up the eCommerce strategy plus the Company raised its outlook. Net revenuegrew 13% to$581.1 millionas total comparable sales increased 7% and comparable store sales increased 2%, or increased by 2% on a constant dollar basis. Direct to consumer net revenue increased 29%, or increased 30% on a constant dollar basis. During the quarter the Company held an online warehouse sale. Excluding the impact of this sale, direct to consumer net revenue increased 15%, or increased 16% on a constant dollar basis. Net income was $48.711 million versus net income of $53.625 million. The Company ended the second quarter of fiscal 2017 with $721.2 million in cash and cash equivalents compared to $535.3 million at the end of the second quarter of fiscal 2016. The CEO commented:

Hot Performing Stocks To Invest In Right Now: HSBC Holdings plc(HSBC)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Up first on our list of financial sector breakout trades is $156 billion global bank HSBC Holdings plc (HSBC) . Don’t get fooled by the headline numbers in HSBC this year – shares may be hovering around breakeven year-to-date, but they’re up more than 35% from their April lows. And after tracking sideways for the last couple of months, HSBC is back in breakout mode this week.

  • [By Elizabeth Balboa]

    Here are the top 10 financial bodies investing in lobbying in 2017:

    American Bankers Association: $5.6 million
    Securities Industry & Financial Market Association: $3.5 million
    Financial Services Roundtable: $3.0 million
    Independent Community Bankers of America: $2.7 million
    Association of International CPAs: $2.6 million
    Citigroup Inc (NYSE: C): $2.5 million
    Investment Company Institute: $2.4 million
    S&P Global Inc (NYSE: SPGI): $2.4 million
    Credit Union National Association: $2.4 million
    HSBC Holdings plc (ADR) (NYSE: HSBC): $2.4 million

    Dozens of others spent more than $1 million, including Ally Financial Inc (NYSE: ALLY), Visa Inc (NYSE: V) and Navient Corp (NASDAQ: NAVI).

  • [By Money Morning News Team]

    And the Aramco IPO is making progress. On Feb. 7, the Saudi Arabian oil company hired Moelis & Co. (NYSE:MC) as its IPO advisor. Then on Feb. 21, the company hired the lead underwriters for the IPO. Wall Street stalwarts JPMorgan Chase & Co. (NYSE: JPM), Morgan Stanley (NYSE: MS), and HSBC Holdings Plc. (NYSE ADR: HSBC) won the lucrative underwriting contracts.

Hot Performing Stocks To Invest In Right Now: Pacific Ethanol Inc.(PEIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Pacific Ethanol Inc (NASDAQ: PEIX) got a boost, shooting up 30 percent to $5.47 after the company reported stronger-than-expected earnings for its fourth quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *